AMO Pharma

[On Demand]
Search General Info
Search Education
Search Partnering Companies
3 clinical stage assets:
AMO-02 in Phase III in Myotonic Dystrophy
AMO-01 in Phelan McDermid Syndrome
AMO-06 in Rett syndrome and Combat PTSD
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
AMO-02 for Myotonic Dystrophy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
AMO Pharma Ltd.